Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O Day, Heiner Dreismann, Applied Biosystems, CombiMatrix



Daniel O'Day has replaced Heiner Dreismann as head of Roche Molecular Diagnostics, Roche said last week. O'Day most recently served as head of operations for Roche Pharmaceuticals in Denmark.

As head of Roche Molecular Diagnostics, O'Day will be responsible for all global functions including research, development, manufacturing, and marketing, as well as site operations in Pleasanton and Alameda, Calif.; Branchburg and Belleville, NJ; and Penzberg, Germany.

O'Day holds a BS in biology from Georgetown University and an MBA from Columbia University.


New Releases

Applied Biosystems last week launched its TargetSeq Resequencing System, which is intended for resequencing smaller genomes and targeted genomic regions using the company's 3730 and 3730xl DNA Analyzers. The TargetSeq system includes a software module for sequencing small DNA stretches of 200 to 400 bases in 20 minutes or less, the company said. The system increases the number of bases read by the 3730 Analyzer to more than 2.8 megabases per day, the company added.

CombiMatrix this week launched upgraded versions of its CustomArray and CustomArray Synthesizer that enable users to synthesize the firm's CustomArray 90K, an array that can contain up to 94,000 features.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.